New combo therapy aims to boost blood health in sickle cell patients
NCT ID NCT05451940
Summary
This study tested whether adding a hormone called erythropoietin (EPO) to the standard drug hydroxyurea could safely improve chronic anemia in adults with sickle cell disease. The small, early-phase trial involved 17 participants who were already on stable hydroxyurea treatment. Researchers measured if the combination increased hemoglobin levels and reduced the need for blood transfusions.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SICKLE CELL DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Lagos University Teaching Hospital
Lagos, 102215, Nigeria
-
UPMC
Pittsburgh, Pennsylvania, 15213, United States
Conditions
Explore the condition pages connected to this study.